Synopsis
Synopsis
0
VMF
DRUG PRODUCT COMPOSITIONS0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Bicarbonate, Lithium
2. Carbonate, Dilithium
3. Carbonate, Lithium
4. Cp 15,467 61
5. Cp-15,467-61
6. Cp15,46761
7. Dilithium Carbonate
8. Eskalith
9. Lithane
10. Lithium Bicarbonate
11. Lithobid
12. Lithonate
13. Lithotabs
14. Micalith
15. Nsc 16895
16. Nsc-16895
17. Nsc16895
18. Priadel
19. Quilinorm Retard
20. Quilinorm-retard
21. Quilinormretard
1. 554-13-2
2. Dilithium Carbonate
3. Lithonate
4. Lithobid
5. Lithane
6. Carbonic Acid, Dilithium Salt
7. Eskalith
8. Lithotabs
9. Carbonic Acid Lithium Salt
10. Liskonum
11. Lithizine
12. Micalith
13. Priadel
14. Limas
15. Eskalith Cr
16. Camcolit
17. Carbolitium
18. Neurolepsin
19. Lithium Carbonicum
20. Nsc-16895
21. Candamide
22. Carbolith
23. Eutimin
24. Hypnorex
25. Lithicarb
26. Lithinate
27. Lithionate
28. Liticar
29. Manialith
30. Maniprex
31. Litard
32. Lithea
33. Plenur
34. Quilonum Retard
35. Pfi-lithium
36. Lithium Phasal
37. Pfl-lithium
38. Litho-carb
39. Cp-15467-61
40. Lithium Carbonate (li2co3)
41. Cp-15,467-61
42. Mfcd00011084
43. 2bmd2gna4v
44. Chebi:6504
45. Carbonic Acid Lithium Salt (li2co3)
46. Lithium Carbonate (2:1)
47. Cp 15467-61
48. Ceglution
49. Phasal
50. Cp-1546761
51. Teralithe [french]
52. Lithium Carbonate Nanoparticles
53. Carbolithium
54. Teralithe
55. Lithium, Reference Standard Solution
56. Dilithium;carbonate
57. Li2 (c O3)
58. Carbonic Acid Dilithium Salt
59. Ccris 3153
60. Hsdb 3351
61. Einecs 209-062-5
62. Unii-2bmd2gna4v
63. Carbolithium Ifi
64. Lithium Qd
65. Eskalith (tn)
66. Lithobid (tn)
67. Lithium Carbonate [usan:usp:jan]
68. Starbld0023766
69. Lithium Carbonate Powder
70. Li2co3
71. Dilithium Trioxidocarbonate
72. Ec 209-062-5
73. Lithium Carbonate [mi]
74. Lithium Carbonate [jan]
75. Chembl1200826
76. Dtxsid1023784
77. Lithium Carbonate (jp17/usp)
78. Lithium Carbonate [hsdb]
79. Lithium Carbonate [inci]
80. Lithium Carbonate [usan]
81. Lithium Carbonate [vandf]
82. Lithium Carbonicum [hpus]
83. Lithium Carbonate [mart.]
84. Lithium Carbonate [usp-rs]
85. Lithium Carbonate [who-dd]
86. Lithium Carbonate [who-ip]
87. Str02638
88. Carbonic Acid, Lithium Salt (1:2)
89. Dilithium Carbonate [who-ip]
90. Lithium Carbonate, Acs Reagent Grade
91. Akos015904647
92. Angc-554-13-2
93. Db14509
94. Lithii Carbonas [who-ip Latin]
95. Lithium Carbonate [orange Book]
96. Lithium Carbonate [ep Monograph]
97. Lithium Carbonate [usp Monograph]
98. B7705
99. Ft-0627895
100. L0224
101. C07964
102. D00801
103. Dilithium Carbonate, Dilithium Salt, Carbonic Acid
104. Q410174
| Molecular Weight | 73.9 g/mol |
|---|---|
| Molecular Formula | CLi2O3 |
| Hydrogen Bond Donor Count | 0 |
| Hydrogen Bond Acceptor Count | 3 |
| Rotatable Bond Count | 0 |
| Exact Mass | 74.01675073 g/mol |
| Monoisotopic Mass | 74.01675073 g/mol |
| Topological Polar Surface Area | 63.2 Ų |
| Heavy Atom Count | 6 |
| Formal Charge | 0 |
| Complexity | 18.8 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 3 |
| 1 of 4 | |
|---|---|
| Drug Name | Lithium carbonate |
| Drug Label | Each capsule for oral administration contains 150 mg, 300 mg or 600 mg of Lithium Carbonate USP.Inactive IngredientsThe capsules contain talc. The hard gelatin shell consists of gelatin, titanium dioxide, sodium lauryl sulphate and FD & C Red 40.The.. |
| Active Ingredient | Lithium carbonate |
| Dosage Form | Tablet, extended release; Tablet; Capsule |
| Route | Oral |
| Strength | 150mg; 600mg; 300mg; 450mg |
| Market Status | Prescription |
| Company | Mylan Pharms; Alembic; Hetero Labs Ltd Iii; Sun Pharm Inds; Hikma Pharms; Roxane; Glenmark Generics |
| 2 of 4 | |
|---|---|
| Drug Name | Lithobid |
| Drug Label | LITHOBID tablets contain lithium carbonate, a white odorless alkaline powder with molecular formula Li2CO3 and molecular weight 73.89. Lithium is an element of the alkali-metal group with atomic number 3, atomic weight 6.94, and an emission line at... |
| Active Ingredient | Lithium carbonate |
| Dosage Form | Tablet, extended release |
| Route | Oral |
| Strength | 300mg |
| Market Status | Prescription |
| Company | Ani Pharms |
| 3 of 4 | |
|---|---|
| Drug Name | Lithium carbonate |
| Drug Label | Each capsule for oral administration contains 150 mg, 300 mg or 600 mg of Lithium Carbonate USP.Inactive IngredientsThe capsules contain talc. The hard gelatin shell consists of gelatin, titanium dioxide, sodium lauryl sulphate and FD & C Red 40.The.. |
| Active Ingredient | Lithium carbonate |
| Dosage Form | Tablet, extended release; Tablet; Capsule |
| Route | Oral |
| Strength | 150mg; 600mg; 300mg; 450mg |
| Market Status | Prescription |
| Company | Mylan Pharms; Alembic; Hetero Labs Ltd Iii; Sun Pharm Inds; Hikma Pharms; Roxane; Glenmark Generics |
| 4 of 4 | |
|---|---|
| Drug Name | Lithobid |
| Drug Label | LITHOBID tablets contain lithium carbonate, a white odorless alkaline powder with molecular formula Li2CO3 and molecular weight 73.89. Lithium is an element of the alkali-metal group with atomic number 3, atomic weight 6.94, and an emission line at... |
| Active Ingredient | Lithium carbonate |
| Dosage Form | Tablet, extended release |
| Route | Oral |
| Strength | 300mg |
| Market Status | Prescription |
| Company | Ani Pharms |
Antidepressive Agents; Antimanic Agents; Antithyroid Agents; Enzyme Inhibitors
National Library of Medicine's Medical Subject Headings online file (MeSH, 1999)
Most prepn currently used in the U.S. are tablets or capsules of lithium carbonate. Slow-release prepn of lithium carbonate also are available, as is a liq prepn of lithium citrate (with 8 mEq of Li+, equivalent to 300 mg of carbonate salt, per 5 mL or 1 teaspoonful of citrate liq). Salts other than the carbonate have been used, but the carbonate salt is favored for tablets and capsules because it is relatively less hygroscopic and less irritating to the gut than other salts, especially the chloride salt. /Li therapy/
Hardman, J.G., L.E. Limbird, P.B., A.G. Gilman. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 10th ed. New York, NY: McGraw-Hill, 2001., p. 511
Lithium /carbonate and citrate/ is indicated as the primary agent in the treatment of acute manic and hypomanic episodes in bipolar disorder, and for maintenance therapy to help diminish the intensity and frequency of subsequent manic episodes in patients with a history of mania. /Included in US product labeling/
Thomson/Micromedex. Drug Information for the Health Care Professional. Volume 1, Greenwood Village, CO. 2007., p. 1844
Lithium /carbonate and citrate/ is used in some patients as the agent of choice in the prevention of bipolar depression. Clinicians have observed a diminished intensity and frequency of severe depressive episodes. /Included in US product labeling/
Thomson/Micromedex. Drug Information for the Health Care Professional. Volume 1, Greenwood Village, CO. 2007., p. 1844
For more Therapeutic Uses (Complete) data for LITHIUM CARBONATE (28 total), please visit the HSDB record page.
Because of potential effects of lithium upon thyroid and renal function, appropriate indices of these functions should be measured prior to start of treatment, then monitored periodically as therapy proceeds.
Miller, R. R., and D. J. Greenblatt. Handbook of Drug Therapy. New York: Elsevier North Holland, 1979., p. 580
Lithium carbonate should not be used in patients with cardiovascular or renal disease. ...Should not be used in children under 12 yr of age.
Osol, A. and J.E. Hoover, et al. (eds.). Remington's Pharmaceutical Sciences. 15th ed. Easton, Pennsylvania: Mack Publishing Co., 1975., p. 1025
Outpatients and their families should be warned that the patient must discontinue lithium therapy immediately and consult a physician if signs of lithium intoxication such as muscle twitching, tremor, mild ataxia, drowsiness, muscle weakness, diarrhea, or vomiting occur. Patients also should be warned that lithium may impair their ability to perform activities requiring mental alertness or physical coordination (e.g., operating machinery, driving a motor vehicle).
McEvoy, G.K. (ed.). American Hospital Formulary Service. AHFS Drug Information. American Society of Health-System Pharmacists, Bethesda, MD. 2007., p. 2570
Lithium should be used cautiously in patients with preexisting cardiovascular or thyroid disease. Patients with underlying cardiovascular disease should be observed carefully for signs and symptoms of arrhythmia (including periodic ECG determinations), and serum lithium concentrations should be kept within the therapeutic range since nodal arrhythmias may occur. Patients with underlying hypothyroidism should have thyroid function (T3, T4, and TSH concentrations) evaluated yearly and be given supplemental thyroid therapy when needed.
McEvoy, G.K. (ed.). American Hospital Formulary Service. AHFS Drug Information. American Society of Health-System Pharmacists, Bethesda, MD. 2007., p. 2571
For more Drug Warnings (Complete) data for LITHIUM CARBONATE (45 total), please visit the HSDB record page.
Lithium is used as a mood stabilizer, and is indicated for the treatment of manic episodes and maintenance of bipolar disorder.
FDA Label
Lithium's mechanism of action is still unknown. Lithium's therapeutic action may be due to a number of effects, ranging from inhibition of enzymes such as glycogen synthase kinase 3, inositol phosphatases, or modulation of glutamate receptors.
Antidepressive Agents
Mood-stimulating drugs used primarily in the treatment of affective disorders and related conditions. Several MONOAMINE OXIDASE INHIBITORS are useful as antidepressants apparently as a long-term consequence of their modulation of catecholamine levels. The tricyclic compounds useful as antidepressive agents (ANTIDEPRESSIVE AGENTS, TRICYCLIC) also appear to act through brain catecholamine systems. A third group (ANTIDEPRESSIVE AGENTS, SECOND-GENERATION) is a diverse group of drugs including some that act specifically on serotonergic systems. (See all compounds classified as Antidepressive Agents.)
Enzyme Inhibitors
Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)
Antimanic Agents
Agents that are used to treat bipolar disorders or mania associated with other affective disorders. (See all compounds classified as Antimanic Agents.)
Absorption
Lithium absorption is rapid and oral bioavailability is close to 100%.
Route of Elimination
Lithium is primarily eliminated through the kidneys and elimination in the feces is insignificant.
Volume of Distribution
Apparent volume of distribution is 0.7 to 1.0L/kg.
Clearance
Clearance is generally between 10 and 40mL/min but may be as low as 15mL/min in elderly patients and those with renal impairment.
... Lithium /carbonate/ crosses placenta and is present in mother and fetus in same concentration.
American Medical Association, Council on Drugs. AMA Drug Evaluations Annual 1994. Chicago, IL: American Medical Association, 1994., p. 313
Lithium /carbonate/ is completely absorbed six to eight hours after oral administration. Since the onset of action is slow (five to ten days), parenteral administration is of no advantage. The plasma half-life is 17 to 36 hours, and this drug is eliminated almost entirely by the kidneys. Lithium clearance averages approximately 20% of creatinine clearance, but significant variability exists among patients.
American Medical Association, Council on Drugs. AMA Drug Evaluations Annual 1994. Chicago, IL: American Medical Association, 1994., p. 313
The population pharmacokinetics of lithium were determined using the nonlinear mixed effects model (NONMEM) program in 79 psychiatric inpatients who were at least 18 yr old, had normal renal function, and were receiving lithium carbonate 2 or 3 times daily. With the initial model, the mean lithium volume of distribution was 32.8 L and the mean lithium clearance was 1.36 L/hr. With an intermediate model, lithium clearance estimates improved on the basis of patient size (weight and body surface area), daily lithium dosage, age, gender, and race. When only the most significant variables, lean body weight and creatinine clearance, were retained, a final model was obtained that yielded a coefficient of variation for lithium clearance of about 24% and gave fairly accurate predictions of steady-state lithium concentrations (coefficient of variation, about 16%). It was concluded that analysis of lithium pharmacokinetics with the nonlinear mixed-effects model program suggested that lean body weight and creatinine clearance are important predictors of lithium clearance.
PMID:2049899 Jermain DE et al; Clin Pharm 10 (May): 376-381 (1991)
Lithium disposition in plasma, red blood cells and urine was studied in acute self-poisoned patient upon chronic lithium therapy (n=4) and in chronic intoxicated patients receiving oral lithium (n=10). Following acute intoxication upon chronic lithium therapy, lithium pharmacokinetics did not differ from previous reports. Terminal plasma half life ranged from 19.0-29.0 hr and RBC/plasma ratio was 0.32 +/- 0.11. the distribution volume of the terminal phase, Vz, was estimated at 0.84 +/- 0.32 L/kg and renal clearance was 0.38 +/- 0.11 ml/mn/kg. After chronic intoxication lithium pharmacokinetics differed from those of the acute patients. Terminal plasma half-life ranged from 36.5-79.4 hr and zero-order decline appeared in 8 of the 10 patients. The RBC/plasma ratio was 0.87 +/- 0.22 on admission. Vz was estimated at 0.71 +/- 0.27 L/kg and renal clearance was 0.16 +/- 0.07 ml/mn/kg. These modifications in lithium elimination kinetics could be related to the decrease in the glomerular filtration rate with age or renal dysfunction in this group of patients.
PMID:7582387 Ferron G et al; Int J Clin Pharmacol Ther 33 (6): 351-5 (1995)
For more Absorption, Distribution and Excretion (Complete) data for LITHIUM CARBONATE (22 total), please visit the HSDB record page.
Lithium carbonate is not metabolized before excretion.
The half life of lithium carbonate is 18 to 36 hours. Other sources say it may be 7 to 20 hours.
The plasma half-life is 17 to 36 hours.
American Medical Association, Council on Drugs. AMA Drug Evaluations Annual 1994. Chicago, IL: American Medical Association, 1994., p. 313
The plasma half-life (in healthy volunteers) shows a considerable variability: from 5 to 40 hr, with most values between 15 and 30 hr, it depends on the duration of treatment as well as on kidney function and age. /Li+/
Chang, L.W. (ed.). Toxicology of Metals. Boca Raton, FL: Lewis Publishers, 1996, p. 455
The usual elimination half-life is 12 to 27 hr, but it may rise to nearly 60 hr if renal excretion is compromised. /Li+/
Klaassen, C.D. (ed). Casarett and Doull's Toxicology. The Basic Science of Poisons. 6th ed. New York, NY: McGraw-Hill, 2001., p. 852
... The elimination half-life averages 20 to 24 hr. /Li+/
Hardman, J.G., L.E. Limbird, P.B., A.G. Gilman. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 10th ed. New York, NY: McGraw-Hill, 2001., p. 508
For more Biological Half-Life (Complete) data for LITHIUM CARBONATE (9 total), please visit the HSDB record page.
Lithium's mechanism of action is still unknown. However, the inositol depletion theory suggests 3 main potential targets. These targets are inositol monophosphatase, inositol polyphosphatase, and glycogen synthase kinase 3(GSK-3). The Inositol depletion theory suggests lithium behaves as an uncompetitive inhibitor of inositol monophosphatase in a manner inversely proportional to the degree of stimulus. This inhibition lowers levels of inositol triphosphate. However, stronger inhibitors of inositol monophosphatase are not as clinically effective and low levels of inositol triphosphate are associated with memory impairment. Lithium acts on inositol polyphosphatase as an uncompetitive inhibitor. This inhibition is thought to have multiple downstream effects that have yet to be clarified. Lithium regulates phosphorylation of GSK-3 which regulates other enzymes through phosphorylation. Lithium can also inhibit GSK-3 through interfering with the magnesium ion in the active site.
Although its antimanic mechanism of action has not been fully determined, lithium is known to affect a variety of neurohumoral signal transduction mechanisms. ... Lithium /lithium carbonate/ counteracts mood changes and is considered the most specific antimanic drug for the prophylaxis and treatment of bipolar disorder.
American Medical Association, Council on Drugs. AMA Drug Evaluations Annual 1994. Chicago, IL: American Medical Association, 1994., p. 311
In animal brain tissue, Li+ at concn of 1 to 10 mEq/L inhibits the depolarization-provoked and Ca+2-dependent release of norepinephrine and dopamine, but not serotonin, from nerve terminals. Li+ may even enhance the release of serotonin, especially in the limbic system, at least transiently. The ion has little effect on catecholamine-sensitive adenylyl cyclase activity or on the binding of ligands to monoamine receptors in brain tissue, although there is some evidence that Li+ can inhibit the effects of receptor-blocking agents that cause supersensitivity in such systems. Li+ can modify some hormonal responses mediated by adenylyl cyclase or phospholipase C in other tissues, including the actions of antidiuretic and thyroid-stimulating hormones on the actions of antidiuretic and thyroid-stimulating hormones on their peripheral target tissues. In part, the actions of Li+ may reflect its ability to interfere with the activity of both stimulatory and inhibitory GTP-binding proteins (Gs and Gi) by keeping them in their less active alpha-beta-gamma trimer state. /Li+/
Hardman, J.G., L.E. Limbird, P.B., A.G. Gilman. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 10th ed. New York, NY: McGraw-Hill, 2001., p. 508
Lithium inhibits the phosphatase that liberates inositol (I) from inositol phosphate (IP) ... Li+ ... can modify the abundance or function of G proteins and effectors, as well as protein kinases and several cell and nuclear regulatory factors. /Li+, from figure/
Hardman, J.G., L.E. Limbird, P.B., A.G. Gilman. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 10th ed. New York, NY: McGraw-Hill, 2001., p. 494
Mechanistically, the Li effect results from its substitution for body cations, eg, sodium and potassium, resulting in multisystemic actions. A partial substitution for normal cations causes changes in ion exchange and transfer in cellular processes. Incorporation of Li into membrane structures may alter responses to hormones and the coupling of energy processes ... Among the factors that may modify Li toxicity and kinetics are the type of the poisoning, the presence of the underlying disease, and renal impairment. /Li+/
Chang, L.W. (ed.). Toxicology of Metals. Boca Raton, FL: Lewis Publishers, 1996, p. 455
For more Mechanism of Action (Complete) data for LITHIUM CARBONATE (22 total), please visit the HSDB record page.
API SUPPLIERS
HRV Global Life Sciences - Market Expansion Leader in Pharmaceuticals.
GDUFA
DMF Review : Reviewed
Rev. Date : 2019-05-06
Pay. Date : 2019-03-25
DMF Number : 33629
Submission : 2019-03-19
Status : Active
Type : II
Certificate Number : CEP 2023-190 - Rev 00
Issue Date : 2024-01-11
Type : Chemical
Substance Number : 228
Status : Valid
Date of Issue : 2023-12-28
Valid Till : 2026-12-28
Written Confirmation Number : WC-0310
Address of the Firm :
NDC Package Code : 66039-947
Start Marketing Date : 2018-12-13
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Registrant Name : Aging Life Science Co., Ltd.
Registration Date : 2023-06-20
Registration Number : 20230612-209-J-1509(A)
Manufacturer Name : Glenmark Life Sciences Ltd
Manufacturer Address : Plot No.Z-103/ I, DAHEJ SEZ Phase II, City : Dahej, District : Bharuch, Gujarat State, India
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 15677
Submission : 2001-10-18
Status : Active
Type : II
GDUFA
DMF Review : Reviewed
Rev. Date : 2013-07-08
Pay. Date : 2013-03-25
DMF Number : 23175
Submission : 2009-10-07
Status : Active
Type : II
GDUFA
DMF Review : Reviewed
Rev. Date : 2024-02-12
Pay. Date : 2023-12-19
DMF Number : 39243
Submission : 2023-12-25
Status : Active
Type : II
GDUFA
DMF Review : Reviewed
Rev. Date : 2018-09-10
Pay. Date : 2018-08-21
DMF Number : 1241
Submission : 1968-09-30
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 34517
Submission : 2020-01-15
Status : Active
Type : IV
Date of Issue : 2022-02-03
Valid Till : 2025-02-02
Written Confirmation Number : WC-0518
Address of the Firm :
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 4293
Submission : 1981-09-29
Status : Inactive
Type : II
Registration Number : 217MF10493
Registrant's Address : Verovskova ulica 57, 1000 Ljubljana, Slovenia
Initial Date of Registration : 2005-09-06
Latest Date of Registration : --
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 3627
Submission : 1979-09-28
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 19158
Submission : 2006-02-03
Status : Inactive
Type : II
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 3773
Submission : 1980-04-18
Status : Inactive
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2013-04-02
Pay. Date : 2013-03-26
DMF Number : 4242
Submission : 1981-08-12
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 3778
Submission : 1980-04-07
Status : Inactive
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2018-09-10
Pay. Date : 2018-08-21
DMF Number : 1241
Submission : 1968-09-30
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 3627
Submission : 1979-09-28
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 15677
Submission : 2001-10-18
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 4293
Submission : 1981-09-29
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 1190
Submission : 1968-05-24
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 3792
Submission : 1980-04-23
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 1074
Submission : 1967-06-27
Status : Inactive
Type : II
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CEP/COS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
Regulatory Info : Originator
Registration Country : South Africa
Brand Name : Camcolit
Dosage Form : TAB
Dosage Strength : 250mg
Packaging : 100X1mg
Approval Date :
Application Number :
Regulatory Info : Originator
Registration Country : South Africa
Regulatory Info : Originator
Registration Country : South Africa
Brand Name : Camcolit
Dosage Form : TAB
Dosage Strength : 250mg
Packaging : 1000X1mg
Approval Date :
Application Number :
Regulatory Info : Originator
Registration Country : South Africa
Regulatory Info : Originator
Registration Country : South Africa
Brand Name : Camcolit
Dosage Form : TAB
Dosage Strength : 400mg
Packaging : 100X1mg
Approval Date :
Application Number :
Regulatory Info : Originator
Registration Country : South Africa
Regulatory Info :
Registration Country : Australia
Brand Name : Lithicarb
Dosage Form : tablet
Dosage Strength : 250 mg
Packaging : 200
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info :
Registration Country : Australia
Brand Name : Quilonum SR
Dosage Form :
Dosage Strength :
Packaging : 100
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info : Prescription
Registration Country : Canada
Brand Name : CARBOLITH
Dosage Form : CAPSULE
Dosage Strength : 150MG
Packaging : 100
Approval Date :
Application Number : 461733
Regulatory Info : Prescription
Registration Country : Canada
Regulatory Info :
Registration Country : India
Brand Name : Brilith-300
Dosage Form : Tablet
Dosage Strength : 300MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Regulatory Info : Generics
Registration Country : Costa Rica
Brand Name : DELITIO®
Dosage Form : TABLET
Dosage Strength : 300MG
Packaging :
Approval Date :
Application Number :
Regulatory Info : Generics
Registration Country : Costa Rica
Regulatory Info : Prescription
Registration Country : Canada
Brand Name : PMS-LITHIUM CARBONATE - CAP 300MG
Dosage Form : CAPSULE
Dosage Strength : 300MG
Packaging : 100/1000
Approval Date :
Application Number : 2216140
Regulatory Info : Prescription
Registration Country : Canada
Regulatory Info : DISCN
Registration Country : USA
Brand Name : LITHIUM CARBONATE
Dosage Form : CAPSULE;ORAL
Dosage Strength : 300MG
Packaging :
Approval Date : 2001-09-27
Application Number : 76121
Regulatory Info : DISCN
Registration Country : USA
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
RLD : No
TE Code :
Brand Name : LITHIUM CARBONATE
Dosage Form : CAPSULE;ORAL
Dosage Strength : 300MG
Approval Date : 1987-03-19
Application Number : 70407
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
RLD : No
TE Code : AB
Brand Name : LITHIUM CARBONATE
Dosage Form : CAPSULE;ORAL
Dosage Strength : 150MG
Approval Date : 2009-01-12
Application Number : 79159
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
RLD : No
TE Code : AB
Brand Name : LITHIUM CARBONATE
Dosage Form : CAPSULE;ORAL
Dosage Strength : 300MG
Approval Date : 2009-01-12
Application Number : 79159
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
RLD : No
TE Code : AB
Brand Name : LITHIUM CARBONATE
Dosage Form : TABLET, EXTENDED RELEASE;ORAL
Dosage Strength : 450MG
Approval Date : 2011-02-14
Application Number : 91616
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
RLD : Yes
TE Code : AB
Brand Name : LITHIUM CARBONATE
Dosage Form : CAPSULE;ORAL
Dosage Strength : 300MG
Approval Date : 1982-01-01
Application Number : 17812
RX/OTC/DISCN : RX
RLD : Yes
TE Code : AB
RLD : Yes
TE Code : AB
Brand Name : LITHIUM CARBONATE
Dosage Form : CAPSULE;ORAL
Dosage Strength : 150MG
Approval Date : 1987-01-28
Application Number : 17812
RX/OTC/DISCN : RX
RLD : Yes
TE Code : AB
RLD : No
TE Code : AB
Brand Name : LITHIUM CARBONATE
Dosage Form : TABLET, EXTENDED RELEASE;ORAL
Dosage Strength : 450MG
Approval Date : 2004-01-05
Application Number : 76691
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
RLD : No
TE Code :
Brand Name : LITHIUM CARBONATE
Dosage Form : CAPSULE;ORAL
Dosage Strength : 300MG
Approval Date : 1989-02-01
Application Number : 72542
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Canada
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Australia
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DRUG PRODUCT COMPOSITIONS
DOSAGE - CAPSULE;ORAL - 150MG
USFDA APPLICATION NUMBER - 17812
DOSAGE - CAPSULE;ORAL - 300MG
USFDA APPLICATION NUMBER - 17812
DOSAGE - CAPSULE;ORAL - 600MG
USFDA APPLICATION NUMBER - 17812
DOSAGE - TABLET, EXTENDED RELEASE;ORAL - 300M...DOSAGE - TABLET, EXTENDED RELEASE;ORAL - 300MG
USFDA APPLICATION NUMBER - 18027
DOSAGE - TABLET;ORAL - 300MG
USFDA APPLICATION NUMBER - 18558
Related Excipient Companies
Rochem International Inc
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]SPI Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Seqens
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Faran Shimi Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Boai NKY Pharmaceuticals Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gangwal Healthcare
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Nanjing Well Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pfanstiehl
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ACG Worldwide
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Actylis
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Aeon Procare
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Alcedo Pharmachem
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Anhui Sunhere Pharmaceutical Excipients Co.,Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Clariant
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Corel Pharma Chem
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DFE Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Finar
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gangwal Chemicals
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Huzhou Sunflower Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Ideal Cures Pvt Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Ingredion Pharma Solutions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Kerry
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Kima Chemical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Lonza Capsugel
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Lubrizol Life Science Health
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Microlex e.U
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Nomisma Healthcare
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Novo Excipients
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pharmatrans-Sanaq
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pluviaendo
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Prachin Chemical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Qianhao Chemical (Hebei) Co., Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Qualicaps
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Roquette
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Seppic
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Shanghai Shenmei Pharmaceutical Technology Co., Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Shanghai Welltone Material Technology Co., Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Shijiazhuang Huaxu Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Sigachi Industries
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]The Dow Chemical Company
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Ulanqab Kema New Material
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Valens Pharmachem
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Vasa Pharmachem
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Zhejiang Huakang Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Excipients by Applications
Fillers, Diluents & Binders
Coating Systems & Additives
Direct Compression
Thickeners and Stabilizers
Controlled & Modified Release
Film Formers & Plasticizers
Lubricants & Glidants
Granulation
Taste Masking
Disintegrants & Superdisintegrants
Topical
Parenteral
Co-Processed Excipients
Solubilizers
Chewable & Orodispersible Aids
Empty Capsules
API Stability Enhancers
Emulsifying Agents
Coloring Agents
Vegetarian Capsules
Rheology Modifiers
Surfactant & Foaming Agents
Soft Gelatin
Digital Content
DATA COMPILATION #PharmaFlow
NEWS #PharmaBuzz
Global Sales Information
US Medicaid Prescriptions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?
